Comparison of clinical characteristics between oligoarthritis and symmetric polyarthritis of patients with psoriasis arthritis
10.3760/cma.j.cn141217-20240111-00021
- VernacularTitle:寡关节炎型与对称性多关节炎型银屑病关节炎临床特征比较
- Author:
Xiuning WEI
1
;
Jinjian LIANG
;
Donghui ZHENG
;
Yingqian MO
Author Information
1. 中山大学孙逸仙纪念医院风湿免疫科，广州 510120
- Keywords:
Arthritis, psoriatic;
Uric acid;
Hyperuricemia
- From:
Chinese Journal of Rheumatology
2024;28(11):813-818
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical characteristics of psoriatic arthritis (PsA) and to raise clinicians′ awareness.Methods:We retrospectively analyzed the clinical characteristics of hospitalized patients with the diagnosis of PsA in our hospital. The PsA were classified according to the Classification of Psoriatic Arthritis (CASPAR) criteria. We compared the clinical characteristics and risk factors between the oligoarthritis type and symmetrical polyarthritis subtypes. Comparing the clinical features of PsA patients with hyperuricemia to those with normal uric acid levels. The t-test was utilized to assess the differences in normally distributed continuous variables between the two groups, while the Mann-Whitney U test was employed for the comparison of skewed distributed continuous variables across the groups. Results:162 PsA patients were included, the average age at PsA onset was (38±15)years old and the average of PsA duration was (7.3±6.6) years, 72.8%(118/162) patients were male. Eighty-nine patients (54.9%) presented with symmetric polyarthritis, and 49 patients (30.2%) with oligoarthritis. The median duration of PsA in patients with oligoarthritis was significantly shorter than patients with symmetric polyarthritis [4.0(0.8, 8.5) years vs. 7.0(2.0 10.0) years, Z=-2.83, P=0.005]. Mean serum uric acid levels [(391±126)μmol/L vs. (334±130)μmol/L, t=2.00, P=0.016] and the proportion of patients with concomitant hyperuricemia [(44.9%(22/49) vs. 23.6%(21/89), χ2=6.68, P=0.010] in patients with oligoarthritis was significantly higher than that of patients with symmetric polyarthritis. Multivariate logistic regression analysis showed that patients with hyperuricemia had a significantly increased risk of presenting with oligoarthritis subtype of PsA [ OR(95% CI)=2.938(1.252, 6.890), P=0.013]. Compared with patients with normal uric acid, PsA patients with hyperuricemia were older in age [(51±13)years vs. (48±16)years, t=-3.30, P=0.001], and had a higher proportion of males [86.0%(37/45) vs. 55.6%(45/81), χ2=11.66, P=0.001] longer median duration of psoriasis (11.0(6.0, 11.5)years vs. 8.5(8.0, 18.0)years), higher proportion of oligoarthritis [51.2%(22/43) vs. 28.4%(23/81), χ2=6.30, P=0.012] and higher proportion of hypertension [20.9%(9/43) vs. 7.4%(6/81), χ2=4.83, P=0.028] and cardiovascular disease [9.3%(4/43) vs. 1.2%(1/81), χ2=2.87, P=0.049] all were with statistically significant differences (all P<0.05). Conclusion:Oligoarthritis subtype of PsA patients have a shorter disease duration, higher serum uric acid level, and a higher proportion of hyperuricemia compared to symmetrical polyarthritis subtype of PsA patients; PsA patients with hyperuricemia are more likely to have oligoarthritis, with a higher risk of concomitant hypertension and cardiovascular disease.
